Ekso Bionics (NASDAQ:EKSO) Coverage Initiated by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Ekso Bionics (NASDAQ:EKSO) in a research note issued to investors on Tuesday. The brokerage issued a hold rating on the stock.

EKSO has been the subject of a number of other research reports. HC Wainwright reiterated a “buy” rating and issued a $9.00 price target on shares of Ekso Bionics in a research note on Tuesday, March 4th. Lake Street Capital decreased their price objective on shares of Ekso Bionics from $2.00 to $1.00 and set a “buy” rating for the company in a research report on Tuesday, March 4th.

Ekso Bionics Stock Down 5.7 %

Shares of NASDAQ:EKSO opened at $0.41 on Tuesday. The firm has a market capitalization of $12.00 million, a PE ratio of -0.64 and a beta of 1.09. Ekso Bionics has a 1 year low of $0.34 and a 1 year high of $1.53. The company has a debt-to-equity ratio of 0.28, a current ratio of 2.81 and a quick ratio of 2.14. The firm’s 50-day moving average is $0.43 and its two-hundred day moving average is $0.60.

Ekso Bionics (NASDAQ:EKSO) last issued its quarterly earnings results on Monday, May 5th. The company reported ($0.12) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.01). The company had revenue of $3.38 million for the quarter, compared to analysts’ expectations of $4.62 million. Ekso Bionics had a negative return on equity of 83.09% and a negative net margin of 62.95%. Analysts predict that Ekso Bionics will post -0.48 EPS for the current year.

Ekso Bionics Company Profile

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.